Telemus Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Telemus Capital’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-10,076	Closed	-$185K	–	407
2020 Q3	$185K	Buy	+10,076	New	+$189K	0.01%	414

Other funds holding KNSA

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Telemus Capital's KNSA Position: Q4 2020 in Review

Telemus Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2020, closing a stake of 10,076 shares — an estimated $185K sold.

Telemus Capital first reported a position in KNSA in Q3 2020 and held it in 1 quarter. The position peaked at $185K in Q3 2020. 108 funds tracked by Wall St. Rank hold KNSA as of Q4 2020.

Telemus Capital reported no remaining Kiniksa Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Telemus Capital sold 10,076 Kiniksa Pharmaceuticals shares in Q4 2020, an estimated $185K.
Telemus Capital first reported a position in Kiniksa Pharmaceuticals in Q3 2020 and held it in 1 quarter.
Telemus Capital's Kiniksa Pharmaceuticals position peaked at $185K in Q3 2020.
108 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2020.

Based on Telemus Capital's 13F filing for Q4 2020, filed 28 Jan 2021.